Novartis AG
NOVN.SWFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
58,446
Cost of Revenue
14,495
Gross Profit
43,951
Gross Margin
75.2%
Operating Income
16,435
Operating Margin
28.1%
Net Income
13,493
Net Margin
23.1%
EPS (Basic)
$7.00
EPS (Diluted)
$7.00
EBITDA
23,408
EBITDA Margin
40.1%
2023
12/31/2023
Revenue
52,726
Cost of Revenue
14,093
Gross Profit
38,632
Gross Margin
73.3%
Operating Income
11,039
Operating Margin
20.9%
Net Income
16,781
Net Margin
31.8%
EPS (Basic)
$8.00
EPS (Diluted)
$8.00
EBITDA
20,628
EBITDA Margin
39.1%
2022
12/31/2022
Revenue
49,111
Cost of Revenue
13,088
Gross Profit
36,023
Gross Margin
73.4%
Operating Income
8,979
Operating Margin
18.3%
Net Income
7,859
Net Margin
16.0%
EPS (Basic)
$4.00
EPS (Diluted)
$4.00
EBITDA
16,591
EBITDA Margin
33.8%
2021
12/31/2021
Revenue
49,691
Cost of Revenue
13,261
Gross Profit
36,430
Gross Margin
73.3%
Operating Income
11,363
Operating Margin
22.9%
Net Income
27,144
Net Margin
54.6%
EPS (Basic)
$12.00
EPS (Diluted)
$12.00
EBITDA
34,933
EBITDA Margin
70.3%
2020
12/31/2020
Revenue
56,385
Cost of Revenue
17,087
Gross Profit
39,298
Gross Margin
69.7%
Operating Income
11,472
Operating Margin
20.3%
Net Income
9,121
Net Margin
16.2%
EPS (Basic)
$4.00
EPS (Diluted)
$4.00
EBITDA
19,448
EBITDA Margin
34.5%